Answering the Bell in Severe Asthma

New Pathways to Optimize Patient Outcomes

As the treatment armamentarium for severe asthma continues to expand, best practices within its management will continue to evolve, guided by the integration of the latest scientific information, evidence-based recommendations, and an accumulated of real-world clinical experience. This POC101 Microlearning Series™ will be led by two expert faculty who will deliver focused education on the latest developments in biologic therapies for severe asthma that target upstream inflammatory mediators of disease. Utilizing a multimedia format that combines text and video, faculty will discuss the placement of new targeted biologic therapies, treatment selection informed by unique patient and disease profiles, and finally, strategies for monitoring effectiveness and switching.

 

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from AstraZeneca.

Image POC101
New Insights Into Severe Asthma Pathophysiology and Treatment

Activity 1

Nicola A. Hanania, MD, MS; Flavia Hoyte, MD
MODULE 1
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 03/29/2023

Image POC101
Clinical Decision-making With New Biologics for Severe Asthma

Activity 2

Nicola A. Hanania, MD, MS; Flavia Hoyte, MD
MODULE 2
Begin Activity

credit amount 0.25

credit type CME/AANP

expiration 03/29/2023

Resource

Answering the Bell in Severe Asthma

New Pathways to Optimize Patient Outcomes